Managed Access Programs for LDK378, Ceritinib

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

NCT01685060 ·Status: COMPLETED ·Phase: PHASE2

Managed Access Programs for INC280, Capmatinib

NCT04741789 ·Status: NO_LONGER_AVAILABLE

A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement

NCT03399487 ·Status: UNKNOWN ·Phase: PHASE2

Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs

NCT06863818 ·Status: ACTIVE_NOT_RECRUITING

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

NCT02784158 ·Status: NO_LONGER_AVAILABLE

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

NCT07140016 ·Status: RECRUITING ·Phase: PHASE1

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

NCT03546894 ·Status: COMPLETED

Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

NCT02638909 ·Status: TERMINATED ·Phase: PHASE2

Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

NCT02271139 ·Status: NO_LONGER_AVAILABLE

A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

NCT02487316 ·Status: WITHDRAWN ·Phase: PHASE4

Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer

NCT00579683 ·Status: COMPLETED

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

NCT04318938 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.

NCT02292550 ·Status: COMPLETED ·Phase: PHASE1

ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants

NCT02737501 ·Status: COMPLETED ·Phase: PHASE3

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges

NCT02336451 ·Status: COMPLETED ·Phase: PHASE2

LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

NCT02040870 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma

NCT02374489 ·Status: TERMINATED ·Phase: PHASE2

A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)

NCT04887519 ·Status: COMPLETED

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

NCT03611738 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma

NCT00207116 ·Status: COMPLETED ·Phase: PHASE1

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

NCT03178071 ·Status: NO_LONGER_AVAILABLE

Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays

NCT04074993 ·Status: UNKNOWN ·Phase: PHASE2

Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1

NCT02034981 ·Status: COMPLETED ·Phase: PHASE2

Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

NCT03410108 ·Status: COMPLETED ·Phase: PHASE2

Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib

NCT06620835 ·Status: RECRUITING ·Phase: PHASE2